Andrea Ashford currently serves as vice president of oncology marketing, US at EMD Serono. Prior to joining EMD Serono, she most recently held the role of therapeutic area lead, immunology and oncology, new business development, North America at Johnson & Johnson. Under her leadership, she developed and executed business development, new product planning and lifecycle management strategies to grow the immunology/oncology Janssen Biotech franchise. She completed the global licensing agreement between Janssen and Pharmacyclics for a hematologic malignancy compound during her time at J & J. Throughout her career she’s held various positions at Allos Therapeutics, where she led the launch of Folotyn for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL), as well as at Schering-Plough Oncology/Biotech and Apple Medical Corporation, Berlex Laboratories and Impath Laboratories.